All eyes on the Fed, big jobs Friday Traders will digest one of the most significant data releases of the summer for its implications on the timing of the first rate hike since 2006.
| By: Evelyn Cheng
As with Greece, Ukraine debt swap may not be the last word *Some people see parallels with Greece. LONDON, Sept 3- Bondholders cheering Ukraine's debt swap face the risk that Kiev will return to the bargaining table within a few years, following the path Greece trod after its 2012 restructuring. Ukraine's sovereign bonds have rallied 40 percent to trade up to 75 cents per dollar of face value following the Aug. 27...
| By: Sujata Rao
French investigators confirm wing part is from Flight 370 PARIS- French investigators have formally identified a washed-up piece of airplane debris found in July on a remote island in the Indian Ocean as part of Malaysia Airlines Flight 370, a Boeing 777 that disappeared more than a year ago with 239 people aboard. "Today it is possible to state with certainty that the flaperon discovered on Reunion July 29, 2015...
Source: The Associated Press
Avalanche of amendments risk burying Italian Senate reform *Renzi wants to slim down Senate, curb its powers. *Premier aims to make Italy more governable. ROME, Sept 3- While most of Rome shut down for the August holidays, a group of parliamentary officials remained hunched over their computers, transcribing a record 513,450 amendments to the government's proposed reform of the Senate.
| By: Crispian Balmer
FOREX-Euro steadies after recent gains with focus on ECB LONDON, Sept 3- The euro steadied on Thursday, having rallied 1.5 percent on a trade-weighted basis since China devalued the yuan last month, with the focus on whether the rise could prompt the European Central Bank to try to talk it down. ECB President Mario Draghi will address a news conference at 1230 GMT, less than an hour after an interest rate decision.
| By: Anirban Nag
Market volatility hinges on central banks: Pro Quincy Krosby, market strategist at Prudential Financial, says policy decisions from the European Central Bank on Thursday, as well as the Fed, could change the path of global financial markets.
Amgen cannot stop imminent sale of Neupogen copycat: U.S. appeals court NEW YORK, Sept 2- A U.S. appeals court has cleared the path for Novartis AG to launch the first biosimilar drug in the United States as it declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen. The U.S. Court of Appeals for the Federal Circuit in July said Novartis could begin to market its biosimilar...